ProCE Banner Activity

My Selections for Key AML Abstracts at ASH 2018

Clinical Thought
The ASH conference in San Diego is highlighting a host of promising new data from clinical trials for improving the treatment of your patients with AML. Here are my choices for the top studies.

Released: December 03, 2018

Expiration: December 02, 2019

Share

Faculty

Farhad Ravandi

Farhad Ravandi, MD

Professor of Medicine
Department of Leukemia
University of Texas M. D. Anderson Cancer Center
Houston, Texas

Provided by

Provided by Postgraduate Institute for Medicine
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Celgene

Daiichi Sankyo, Inc.

Jazz Pharmaceuticals, Inc.

Faculty Disclosure

Primary Author

Farhad Ravandi, MD

Professor of Medicine
Department of Leukemia
University of Texas M. D. Anderson Cancer Center
Houston, Texas

Farhad Ravandi, MD, has disclosed that he has received consulting fees from Agios, Amgen, Ariad, Astellas, Jazz, and Orsenix and funds for research support from AbbVie, Amgen, Bristol-Myers Squibb, Seattle Genetics, and Xencor.